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1. Introduction
Ovarian tumors are thought to arise from the surface
epithelium of the ovaryand are classiﬁed into four ma-
jorhistologicclasses: serous,mucinous,endometrioid,
clear cell and (reviewed in [1]). The molecular and
cellular mechanisms of ovarian tumorigenesis remain
unknown and are likely to vary between the different
histotypesofovariancancer[2]. 12–15%ofall ovarian
neoplasms are mucinous ovarian tumors. The majority
(75%) of mucinous tumors are benign, 15% are malig-
nant and the remaining 10% of tumors are borderline
or low malignant potential (LMP).
Mucinousovariantumors possess clinical character-
istics that distinguishthem fromovariantumorsof oth-
er histotypes. A proportion of mucinous ovarian tu-
mors are believed to undergo a unique process of se-
quential development (Fig. 1); beginning as a benign
cyst and progressing to an LMP tumor before devel-
oping into an adenocarcinoma [3,4]. This model of
tumor progression is speciﬁc to the mucinous histo-
type of ovarian tumors (both low- and high-grade tu-
mors) and differentiates them from ovarian tumors of
other histological origins. It is supported in part by the
observation of the co-existence of benign, LMP and
malignant pathologies within the same tumor by elec-
tron microscopy and histological studies [3,5,6]. The
presenceof identical K-ras mutations in these different
pathologicregionsofthetumorlendsfurthersupportto
the tumor progression model [7]. Hierarchical cluster-
ing and binary tree analysis of gene expressionproﬁles
of mucinous tumors of the ovary revealed that muci-
nous cystadenomas were distinct from the other muci-
noussampleswhilemucinousLMPandlow-grademu-
cinous adenocarcinomaswere nearly indistinguishable
from each other [8]. When serous tumors were includ-
ed in the analysis, the results demonstrated that while
mucinousLMP andlow-grademucinousadenomcarci-
nomas remained nearly indistinguishable, serous LMP
and serous adenocarcinoma tumors were grouped in
distinct branches[8]. These results add further support
to the conceived model for mucinous tumor progres-
sion. This model suggests that mucinous tumors of
the ovary differ from other histotypes in that they do
not develop de novo but rather develop from benign or
LMP tumors, thus indicating the potential presence of
biomarkers that may be unique to the mucinous histo-
type.
Patients with LMP mucinoustumors in general have
a good prognosis after surgery since most of these tu-
mors are diagnosedat an early stage and the 5-year cu-
mulative survival rate for women with LMP is 97.0%
(± 1.5%) [9]. However, women with advance stage
mucinous adenocarcinoma tumors respond poorly to
standard platinum-based chemotherapy compared to
women with ovarian tumors of other histotypes and
have a signiﬁcantly reduced 5-year survival rate of
67.4% [9–13].
The diagnosis of mucinous carcinoma of the ovary
is challenging. Many mucinous tumors have a mixed
histology (such as a high frequencyof intestinal differ-
entiation) and are difﬁcult to recognize with standard
pathology (reviewed in [14]). It is believed that 7 to
17%ofallovariantumorsaremetastaticratherthanpri-
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Fig. 1. Mucinous tumor of the ovary containing increasing degrees aggressiveness (presented with permission of Samuel Mok).
mary [15] and the histologic features of metastatic mu-
cinous ovarian carcinomas can be very similar to those
ofprimarymucinousovariantumors[16]. Histopathol-
ogyin combinationwith gross examinationcan be use-
ful in distinguishing primary and metastatic mucinous
tumors. Features including bilaterality, microscopic
surface involvement of epithelial cells, nodular pattern
of growth, an inﬁltrative invasivepattern and growthin
the ovarian hilus are favored in metastatic cases while
size > 10 cm, a smooth tumor surface, benign or bor-
derlineareas, anexpansileinvasivepattern,microscop-
ic cysts > 2 mm, complex papillary epithelial growth
andintraluminalnecroticmaterialarefavoredinprima-
rytumors[17]. However,theseguidelinesarenotcom-
pletely reliable and may not be applicable to late-stage
mucinous tumors of the ovary.
The clinical characteristics of mucinous ovarian tu-
mors (better survival rates for patients with LMP mu-
cinous ovarian tumors versus those with advanced
mucinous adenocarcinoma, differential response to
chemotherapyandsimilar histologiesbetweenprimary
and metastatic mucinous tumors of the ovary) neces-
sitates the identiﬁcation and validation of biomarkers
thatcanimprovespeciﬁcdetection,diagnosisandprog-
nosis of mucinous tumors of the ovary. DNA microar-
rays permit simultaneous, comprehensive, genome-
wide monitoring of gene expression. Gene expression
proﬁlinghasbeenappliedincancerresearchtoidentify
important genes or pathways that molecularly classify
tumors, contribute to carcinogenesis, predict chemore-
sponseorserveasbiomarkersofclinicalcharacteristics
including diagnosis and prognosis (reviewed in [18]).
These studies have provided a basis for the develop-
ment of personalized medicine (reviewed in [19]).
2. Gene expression proﬁling for identiﬁcation of
mucinous-speciﬁc biomarkers
Gene expression proﬁling has been utilized to iden-
tify potential tumor biomarkers that can be used in
clinical applications (including detection, diagnosis
and prognosis) in a variety of tumor types including
prostate [20–23], colon [24], breast [25,26] and ovari-
an cancer [27–31]. More speciﬁcally, gene expression
proﬁling has been applied to identify genes that differ-
entiate between different histotypes of ovarian cancer
aswellasgenesexpressedinspeciﬁcsubtypesthatmay
play a role in their particular clinicopathology.
In a small study, Ono et al. compared gene ex-
pression patterns in ovariantumorsamples versus their
corresponding non-cancerous ovarian tissue as well as
genesthatweredifferentiallyexpressedbetweenserous
and mucinous tumors [32]. The authors analyzed gene
expression proﬁles of ﬁve serous and four mucinous
ovarian adenocarcinomas and patient-matched normal
ovarian tissue using a custom-made cDNA microar-
rays consisting of 9,121 genes. The study revealed
115 differentially expressed genes between mucinous
and serous tumors [32]. Creatinine kinase B, myosin
heavy polypeptide 11 and A28-RGS14p, a p53 target
gene and regulator of G protein signaling, were ex-
pressedathigherlevelsinmucinoustumors[32]. Over-
expressionofA28-RGS14phaspreviouslybeenshown
to inhibit G protein-coupled receptor activation of the
mitogen-activated protein kinase signaling pathway in
various carcinoma cell lines [33]. Thus, A28-RGS14
mayplay a role in the progressionof mucinoustumors,
presumably through regulation of cellular signaling in
response to growth factors acting through G protein-
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In a larger study, Marquez et al. investigated the
molecular alterations contributing to differences be-
tween the histotypes of ovarian cancer [34]. The au-
thorsutilizedtheAffymetrixHumanGenomeU95plat-
form to compare gene expression proﬁles of 50 to-
tal epithelial ovarian cancer samples, including 9 mu-
cinous tumors, with proﬁles of normal ovarian sur-
face epithelium taken directly from patients. Hierar-
chical clustering of all samples clearly distinguished
most of the mucinous samples from the rest of the tu-
morsand, interestingly,theywere clusteredin a branch
with normal samples [34]. Further analysis of genes
whose expression was differentially expressed by at
least 2-fold between the histotypes and differed from
normal ovarian surface epithelium revealed 46 genes
differentiallyexpressed in mucinous tumors. Based on
quantitativereal-timePCR validation,themostspeciﬁc
biomarkersformucinoustumorsversusovariantumors
of other histotypeswere TFF1 (involvedin immunere-
sponse, cellular defense, mucosal maintenance and re-
pair),AGR2,LGALS4andCEACAM6(allinvolvedin
extracellular matrix formation and cell adhesion) and
CTSE (involved in metabolism and proteolysis). The
AGR2 gene is an estrogen-responsive gene whose role
in mucinousovariantumorigenesisis currentlyunclear
but has been shown to be over-expressed in prostate
cancer [35] and is involved in breast cancer metasta-
sis [36]. Schwartz et al. reported that TFF1 gene and
protein expression is speciﬁcally up-regulated in mu-
cinous tumors [37]. TFF1 is a secreted peptide that
belongs to the trefoil factor family and its gene expres-
sion is induced by estrogen and FGF2. It regulates
severalsignaltransductionpathwaysincludingthePI3-
kinase/Akt pathway, the MAPK pathway, and other
pathways involved in cell progression and transforma-
tion (reviewed by [38]). With the exception of CTSE,
these genes have been identiﬁed as mucinous-speciﬁc
ovariantumorbiomarkersby otherstudies discussedin
this review.
Heinzelmann-Schwarz et al. studied the genetic ba-
sis of mucinous ovarian carcinomas and identiﬁed po-
tential markers that distinguish mucinous tumors from
ovarian tumors of other histotypes [39]. The authors
utilized a customized Affymetrix oligonucleotide mi-
croarray to proﬁle gene expression from 3 mucinous
ovarian tumors, 4 mucinous borderline tumors, 8 en-
dometrioid ovarian tumors, 31 serous ovarian tumors
and 4 normal ovary samples [39]. Forty genes were
identiﬁed as up-regulated and 4 genes were identiﬁed
as down-regulated in mucinous ovarian tumors com-
pared to normal ovarian tissues. Of the 40 genes
up-regulated in mucinous ovarian tumors, 13 genes
were unique to mucinous and not found to be differ-
entially expressed in ovarian tumors of other histo-
types. These potential mucinous-speciﬁc biomarkers
include LGALS4, MUC13, MUCDHL, CEACAM5,
CALML4, ARHGAP27, NMES1, BCLP, CDN17 and
TFF1 [39]. The authors demonstrate that mucinous
ovarian tumors over-express genes associated with
mucin production and intestinal function. This study
identiﬁed genes that were also found in other studies
such as TFF1, which has been shown in previous stud-
ies to be up-regulated in other mucinous adenocarci-
nomas, including the study by Marquez et al. dis-
cussed above [34]. Other genes identiﬁed as specif-
ically up-regulated in mucinous tumors both in this
study as well as in the study by Marquez et al. in-
clude CEACAM6, a member of the carcinoembryon-
ic antigen family shown to be over-expressed in many
different cancers including ovarian, breast and colon
cancer [40], and LGALS4, an intestinal-type cell ad-
hesion molecule shown to be over-expressedin several
other epithelial cancers including intestinal, breast and
liver [41,42]. LGALS4 is a potential candidate for an
early mucinous biomarker, due to its lack of expres-
sion in normal ovary and its high expression in mu-
cinous cysts and LMP tumors. LGALS4 is not a se-
creted protein and therefore its clinical relevance as a
diagnosticbiomarkermay be limited; howeverthe pro-
tein contains an extracellular component that may be
useful for detection and measurement [39,42]. CEA-
CAM6 is a membrane-associated protein that interacts
with other members of the CEA family and integrin
receptors to promote cellular adhesion [43]. However,
becauseit has beenshownto be over-expressedin mul-
tiple tumors, its use as a mucinous-speciﬁc diagnostic
biomarkermay be limited and has not been extensively
investigated.
Wamunyokoli et al. have conducted the largest pro-
ﬁling study to date on mucinous tumors of the ovary.
They analyzed multiple mucinous specimens of differ-
ing histologic grade, all of which have been microdis-
sected. The study sought to uncover potential markers
that distinguish between the various mucinous histo-
logical subtypes [8]. Gene expression proﬁles of 25
mucinous tumors were compared to gene expression
proﬁlesof40seroustumorsand10normalovariansur-
face epithelial samples using the Affymetrix Human
Genome U133 Plus 2.0 platform. Unsupervised hier-
archical clustering of all samples revealed 2 arms; nor-
malovariansurfaceepithelialsamplesandserousLMP
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while serous adenocarcinomas and mucinous tumors
clustered in different branches on the second arm, with
high-grade mucinous adenocarcinomas forming a dis-
tinct branch. These results aresuggestiveofa moreag-
gressive phenotype associated with mucinous tumors
and suggest the existence of a subset of genes that
areco-regulatedinhigh-gradeserousadenocarcinomas
and mucinous tumors. A list of genes whose expres-
sion is unique to the mucinous phenotype was extract-
edbycomparinggenesthatare differentiallyexpressed
in mucinous or serous tumors versus normal ovarian
surface epithelium and selecting only those genes that
are up-regulated in mucinous tumors. From this list
of genes, potential biomarkers with clinical relevance
were identiﬁed based on whether they were secreted or
membrane-bound. The potential biomarkers identiﬁed
for mucinous tumors were AGR2, FAM3B, MUC13,
IER3, ADD3 and SLC12A2.
Further analyses were performed to identify genes
that may contribute to mucinous ovarian tumor pro-
gression and reveal potential markers that distinguish
between the various mucinous histological subtypes.
NET1, ERBB3, H63, TSPAN8, ANXA2, GLTSCR2
and CCAR1 were identiﬁed as up-regulated in both
LMP and adenocarcinomamucinous tumors but not in
cystadenoma; TPT1, CTNNA and TACSTD1 were up-
regulated in LMP tumors only and TMEM50A, RAC1
and CTTN were up-regulated in adenocarcinoma tu-
mors only. Some of these genes have been demon-
strated in previous studies to be related to tumor pro-
gression. Over-expression of NET1in NIH3T3 cells
results in increased tumorigenicity [44] and ERBB3
promotesgrowthsandinvasivenessin lungadenocarci-
noma [45]. RAC1 is a rhoGTPase that has been shown
to be involvedin ovariantumor migrationand progres-
sion [46]. Therefore, these genes may play a role in
transformation of mucinous tumors. This study was
successful in identifying several potential novel mark-
ersthat maybeusefulindistinguishingmucinousovar-
ian tumors from ovarian tumors of other histotypes as
well as distinguishing between the various mucinous
subtypes.
3. Protein expression analysis for identiﬁcation of
mucinous-speciﬁc biomarkers
Gene expression proﬁling can be used successful-
ly to identify potential tumor biomarkers. However,
it is clear that the most clinically relevant biomark-
ers are those that are secreted during development and
in early stage of tumor growth. Recent studies have
applied such techniques as immunohistochemistryand
proteomic techniques to identify putative ovarian can-
cer biomarkers (reviewed in [15]). While the number
of these studies is limited, they reveal meaningful in-
formation regarding epithelial ovarian carcinogenesis
progression, diagnosis and prognosis.
In an effort to classify different histotypes of ovar-
ian epithelial tumors and identify surrogate biomark-
ers indicative of ovarian tumors, An et al. utilized 2-
dimensional PAGE proteomics to create distance trees
basedonvariationsofproteinexpressionpatternswith-
in and between 12 ovarian epithelial tumors including
4 serous, 5 mucinous and 3 endometrioid tumors [47].
The results of the distance map trees demonstratedthat
while the tumor samples were separate from normal
ovary, mucinous carcinomas exhibited protein expres-
sion patterns most closely related to normal ovarian
samples. The most aggressive mucinous tumor types
were separate from the LMP tumors, yet more similar
to each other than to otherovarianepithelial tumorhis-
totypes [47]. Six potential biomarkers (NM23-H1, an-
nexin1,proteinphosphatase-1,ferritinlightchain,pro-
teasomeα-6andNAGK)wereidentiﬁedwhoseexpres-
sionswere increasedbyat least 2-foldinovariantumor
samples compared to normal ovary tissues. These pro-
tein products were not speciﬁc for the mucinous histo-
typeandthusmayonlybeusefulasgeneralbiomarkers
for the diagnosis of ovarian cancer. Nonetheless, the
ﬁndings of this study suggest that proteomic proﬁling
can be a valuable tool for the future identiﬁcation of
potential biomarkers that are unique to the mucinous
histotype.
4. Identiﬁcation of biomarkers to distinguish
between primary and metastatic mucinous
tumors
Primary ovarian mucinous tumors are difﬁcult to di-
agnose as they are often confused with metastatic mu-
cinous cancer resulting from other origins. As a re-
sult of their mixed histology, clinicians and patholo-
gists must also rely on other clinical features includ-
ing bilaterality, tumor dissemination pattern as well as
cytology/histology to reliably ascertain the origin of
the tumor [14,17,48,49]. As a result, several immuno-
histochemcial studies have been performed to identi-
fy biomarkers that can aid in distinguishing between
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A study published by Ji et al. sought to identify
biomarkers that can differentiate between primary and
metastatic mucinous ovarian carcinomas. The authors
examined the immunohistochemical expression of cy-
tokeratins CK7 and CK20, the nuclear transcription
factor DPC4 (also known as SMAD4) and the gastric
mucin MUC5AC in 57 primary ovarian mucinous tu-
mors(41LMPand16malignant)and46metastaticmu-
cinous tumors of the ovary [50]. The ﬁndings demon-
strated that almost all (98–100%)primary ovarian mu-
cinous tumors expressed CK7, DPC4 and MUC5AC
while a smaller portion (68%) expressed CK20. Some
of these markers were also expressed in a majority of
metastatic tumors of the ovary(i.e. 100% of pancreatic
cancer cases expressed CK7 and 100% of colorectal
cancers expressed CK20), suggesting that these mark-
ers alone may not be useful in distinguishing between
primary ovarian mucinous carcinoma and metastatic
mucinouscarcinomas. Someoftheexaminedbiomark-
ers were expressed to a lesser extent in metastatic tu-
mors of the ovary. Only 33% of colorectal carcino-
mas expressed CK7 and/or MUC5AC and only 54%
of pancreatic carcinomas expressed DPC4. The re-
sults of the study suggest that combined expression of
both CK7 and CK20 is the most appropriate to distin-
guish between primary mucinous tumors of the ovary
and metastatic colorectal tumors while loss of DPC4
expression can distinguish between primary mucinous
tumors of the ovary and metastatic pancreatic carcino-
mas [50].
It has been reported that approximately 40% of
metastatic tumorsof the ovaryoriginatesfromcolorec-
tal cancer [16]. Because the development of colon
cancer relies on Wnt signaling through β-catenin [51],
Chou et al. sought to determine whether β-catenin
expression could also be used to differentiate between
ovarian mucinous carcinoma and metastatic colorectal
adenocarcinoma [52]. The study analyzed expression
of β-catenin, along with CK7, CK20 and CEA in 43
primaryovarianmucinouscarcinomasand23metastat-
ic colorectal adenocarcinomas by immunohistochem-
istry [52]. Expression of β-catenin was detected in
most (83%) of metastatic colorectal adenocarcinomas
and only 9% of primary ovarianmucinouscarcinomas.
Consistent with the Ji study [50], CK7 was expressed
in a majority (79%) of mucinous ovarian tumors and
only 23% of colorectal samples while CK20 was ex-
pressedinmostcolorectaladenocarcinomas(87%)and
only 44% of mucinous ovarian tumors expressed the
protein. Inaddition,CEA was foundtobe expressedin
70% of mucinous carcinomas, similar to gene expres-
sion proﬁle studies [34,39]. However, CEA was also
expressed in 95% of colorectal carcinomas, suggesting
that while it may be able to differentiate mucinous tu-
morsoftheovaryfromotherovarianhistotypes,itdoes
not serve as an appropriate biomarker to distinguish
betweenprimaryandmetastaticmucinoustumors. The
results of this study support the conclusion that CK7,
CK20 and β-catenin expression may be used to distin-
guish between primary mucinous tumors of the ovary
and metastatic colorectal tumors [52].
Another gene that has been studied as a potential
biomarker for metastatic mucinous tumors is CDX2, a
transcription factor expressed in most colorectal carci-
nomas that is involved in intestinal development, pro-
liferation and differentiation [53,54]. Several studies
have examined its expression in primary mucinous tu-
mors of the ovary, with inconsistent results (reviewed
in[14]). SomehavesuggestedthatexpressionofCDX2
in mucinous tumors of the ovary is dependent on cell
type (endocervical or intestinal) [55,56]. A few stud-
ies have been performedthat have analyzed expression
of CDX2 in coordinationwith other, better-established
mucinous ovarian tumor biomarkers including CK7,
CK20 and β-catenin in an effort to increase their sen-
sitivity. Most studies detect CDX2 expression in all
colorectal carcinomas examined; however expression
of CDX2 in mucinous tumors of the ovary varies in the
different studies. One study examined the expression
of CDX2, CK7 and CK20 by immunohistochemistry
and CDX2 was detected in 100% of mucinous tumors
of the ovary [57]. Other immunohistochemical studies
detectedCDX2inonly40%[58]and21%ofmucinous
tumors of the ovary [56]. It appears that CDX2 alone
is not a useful biomarker for distinguishing between
primary and metastatic mucinous tumors of the ovary.
5. Challenges of applications of biomarkers to
clinical issues of mucinous tumors of the ovary
Geneexpressionproﬁlingandproteomicapproaches
have been demonstratedto be useful techniques for the
identiﬁcation of mucinous-speciﬁc biomarkers. Sever-
al biomarkers identiﬁed by gene expression proﬁling
(includingTFF1, AGR2, LGALS4, CEACAM5, CEA-
CAM6 and MUC13) are speciﬁcally present in muci-
nous tumors of the ovary and could be useful in dis-
tinguishing mucinous ovarian cancers from ovarian tu-
mors of otherhistotypes. With the exceptionof AGR2,
these markers are also expressedto differentdegreesin
tumorsofotherorigins,particularlythosefromthegas-394 G. Samimi et al. / Biomarkers of mucinous tumors of the ovary
Table 1
Summary of biomarkers discussed in this review
Biomarker Gene/Protein Ovarian cancer
histotypes
Other mucinous
carcinomas
Reference
TFF1
(Trefoil Factor Family 1)
Gene, Protein Up-regulated in mucinous Expressed in colorectal
carcinomas [38]
[34,37,39]
AGR2
(Anterior Gradient
2 homolog)
Gene Up-regulated in mucinous Down-regulated in
colorectal carcinomas
versus normal [59]
[8,34]
LGALS4
(Galectin 4)
Gene, Protein Up-regulated in mucinous Expressed in colorectal
carcinomas [41]
[34,39]
CEACAM5
CEACAM6
(Carcinoembryonic
antigen-related cell
adhesion molecule)
Gene Up-regulated in mucinous Expressed in 95% colorectal
carcinomas [52]
[34,39]
MUC13
(Mucin 13)
Gene Up-regulated in mucinous Expressed in colorectal
carcinomas [60]
[8,39]
CK7
(Cytokeratin 7)
Protein Expressed in most mucinous (79–
100%)
Expressed in some colorectal
carcinomas (23–33%)
[50,52]
CK20
(Cytokeratin 20)
Protein Expressed in some mucinous (44–
68%)
Expressed in most colorectal
carcinomas (87–100%)
[50,52]
CDX2 Protein Inconsistentexpressioninmucinous Expressed in all colorectal carcinomas [56–58]
DPC4
(Deleted in
pancreatic cancer
locus 4; SMAD4)
Protein Expressed in all mucinous (100%) Expressed in 89% colorectal and 54%
pancreatic carcinomas
[50]
β-catenin Protein Expressed in only 9% mucinous Expressed in 83% colorectal
carcinomas
[52]
trointestinal track (summarized in Table 1). Therefore,
their use as biomarkers to distinguish between primary
mucinoustumorsoftheovaryandmetastaticmucinous
tumors is limited.
Taking into account the immunohistochemical ﬁnd-
ings presented in this review, it appears that the most
valuable approach to biomarker screening for differ-
entiating primary mucinous tumors of the ovary and
metastatic mucinous tumors is to compare coordinated
expressionof multiplebiomarkers. Currently,the most
commonlyused biomarkersare CK7 and CK20, with a
CK7+/CK20-proﬁlebeingindicativeofprimarymuci-
nous tumors of the ovary while a CK7-/CK20+ proﬁle
is indicative of a metastatic mucinous tumor (reviewed
in [49]). These proﬁles are limited as CK7 has been
shown to be expressed in some colorectal carcinomas
andCK20hasbeenshowntobeexpressedinsomemu-
cinous ovarian tumors (summarized in Table 1). These
proﬁles could be made more reliable by applying ad-
ditional biomarkers. As an example, AGR2 gene ex-
pression has been shown to be up-regulated in muci-
nous tumors and down-regulatedin colorectal cancers.
Therefore, coordinated expression of CK7, CK20 and
AGR2 could potentiallybe more reliable to distinguish
between mucinous tumors of the ovary and metastatic
tumors from the colon. A CK7+/CK20-/AGR2+ pro-
ﬁle would be more indicative of primary mucinous tu-
mors of the ovarywhile a CK7-/CK20+/AGR2- proﬁle
wouldbemoreindicativeofa metastaticmucinouscol-
orectaltumor. Expressionofmultiplebiomarkerscoor-
dinated with the gross/histologic proﬁles as described
above(e.g.bilaterality,invasivepatternsandsize)could
furtherreﬁne the distinction between mucinoustumors
of the ovary and metastatic mucinous tumors.
6. Conclusions
Similarities between primary and metastatic muci-
nous tumors of the ovary make them difﬁcult to accu-
rately diagnosis. The identiﬁcation of biomarkers that
can distinguish primary from metastatic mucinous tu-
morsand/orareuniquetomucinoustumorsoftheovary
could be used in combination with histologic features
of the tumor to signiﬁcantly improve early diagnosis,
and consequently improve patient prognosis.
Geneexpressionproﬁlingandproteomicanalysisare
valuable tools for molecular characterization of vari-
ous mucinous tumors of the ovary and the identiﬁca-
tion of mucinous-speciﬁc biomarkers (summarized in
Table1). All potentialmarkerswill needextensiveval-
idation before they can be used clinically to improve
detection and diagnosis.G. Samimi et al. / Biomarkers of mucinous tumors of the ovary 395
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